Nouvelle déclaration d'incident
No de la demande: 2020-2260
Numéro de référence du titulaire d'homologation: 2019-CA-000044
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: CANADA
État: UNKNOWN
ARLA No d'homologation 29930 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Hartz UltraGuard OneSpot Flea and Tick Cat Drops
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Propriétaire de l'animal
Cat / Chat
Domestic Shorthair
1
Femme
0.92
Inconnu
Cutanée
Unknown / Inconnu
<=30 min / <=30 min
Système
Unknown / Inconnu
Non
Non
Unknown/Inconnu
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 01-Jul-2019, an 11 month old, neutered, female Domestic Shorthair cat, of unknown weight and condition, with concomitant medical condition of fleas, was administered 1 tube of Hartz UltraGuard OneSpot Flea and Tick Cat Drops (S Methoprene) via the topical route by the animal owner. The product was applied between the cat's shoulder blades. Approximately five minutes post application, the cat developed hypersalivation and was offered a treat and water. Approximately five minutes post onset, the hypersalivation resolved and the cat developed lethargy. The cat had not been evaluated by a veterinarian, no treatment had been performed and the clinical sign continued. Veterinary evaluation was recommended if the clinical sign persisted or worsened. No further information was received in this case.
Mineure
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.